United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis


United States Pain Management Therapeutics Market is expected to reach US$ 33.71 Billion by 2030, according to Renub Research. Physical and mental pain has a significant influence on life. It can hinder our daily activities, limit our mobility, and dampen our spirits. Advancements in medical technology and growing awareness have opened up new possibilities in pain management. Medications have traditionally been frequently used in pain treatment to ease or suppress discomfort caused by a variety of disorders. Recognizing the need for new ways, the healthcare sector has focused on the development of pain monitoring devices.

Pain monitoring devices offer a non-invasive and objective means of assessing an individual's pain experience. By providing healthcare professionals with quantitative data, these devices enable personalized treatment plans and help optimize the effectiveness of pain management strategies. Individuals are becoming more aware of the advantages of pain management devices, especially when compared to opioids, which is boosting demand for these novel solutions. The pharmaceutical industry expansion and innovation in the production of pain-relieving drugs creates potential for the US pain management medication market. Factors such as an increase in pain disorders, improved healthcare infrastructure, and demand for safer and more effective pain drugs are driving market growth. The rising number of health-conscious customers, as well as the incidence of chronic illnesses among the elderly, contributes to the market expansion.

United States Pain Management Therapeutics Market will register a CAGR of 3.65% from 2022 to 2030

Elderly individuals, who often experience chronic pain due to joint disorders and various surgeries, require prescribed pain medications, further driving the growth of the U.S. pain management drug market. The rise in cases of diabetic neuropathies, which lead to pain, also contributes to the market expansion. Educational efforts by various organizations and the government regarding pain disorders and proper pain management play a significant role in raising awareness. With the introduction of e-commerce, companies have gained a vital tool that allows customers to conveniently access products and services.

In the context of pain management, health apps and online platforms provide animations and educational resources to inform people about the appropriate dosages and frequencies of pain medications, thereby contributing to the growth of the U.S. pain management drug market. Increased promotional activities by manufacturers and growing awareness among the general population about the proper treatment of pain disorders are expected to fuel the adoption of pain management medications in the future. The area of pain treatment is changing, and the incorporation of new technology and pharmaceuticals offers enormous potential for improving the lives of those who are in pain. The future of pain treatment is brighter, with a focus on personalized methods and a shift away from opioids, bringing hope for a better quality of life for people in need. The United States Pain Management Therapeutics Market was valued at US$ 25.31 Billion in 2022.

United States, pharmaceutical organization performs substantial research, development, and marketing of pain management medications

By Therapeutics, the United States Pain Management Therapeutics Market is segmented into Pharmaceuticals and Devices. The United States pharmaceutical Pain Management Therapeutics Market is a dynamic and rapidly evolving sector within the healthcare industry. As the population ages and chronic pain becomes increasingly common, the demand for effective pain management methods grows. In recent years, there has been a shift in attention toward developing unique and targeted pain management drugs that give more pain relief while lowering the risk of addiction and harmful side effects. As a result, new pharmaceutical items and therapies have entered the market. Advancements in technology and understanding of pain mechanisms drive innovation, such as targeted therapies, precision medicine, and alternative options like medical cannabis. The market is dynamic, aiming to meet the growing demand for effective pain relief. Advancing medications, technology, and treatments holds promise for enhancing the lives of individuals in pain.

Neurostimulation has emerged as the fastest-growing segment in the U.S. pain management drug market

By Devices, the United States Pain Management Therapeutics Market is divided into Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion pumps, and Neurostimulation. Neurostimulation is rapidly gaining momentum in the U.S. pain management drug market. With its implanted devices delivering electrical impulses to nerves, it offers targeted relief for chronic pain conditions. Its effectiveness in reducing pain and improving quality of life has fueled its growth. The market for neurostimulation devices is increasing because they provide a viable alternative to traditional pain drugs, answering the need in the United States for safer and more tailored pain treatment options.

Opioids hold the largest share of the United States pain management drug market.

By Drug Class, the United States Pain Management Therapeutics Market is classified into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, opiates, and Non-narcotic Analgesics. While opioids are excellent pain relievers, their increasing usage has generated concerns owing to the potential of addiction and other negative side effects. Efforts are being undertaken to address these difficulties through the implementation of tougher restrictions, the promotion of responsible prescription practices, and the investigation of alternative pain management choices. In order to achieve a balance between effective pain relief and reducing the risks associated with opioid use, the market is changing toward safer and more customized medications, as well as non-pharmacological alternatives.

Cancer pain is experiencing rapid growth within the U.S. pain management drug market

The Pain Management Therapeutics Market in the United States is classified as Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-operative Pain, Migraine, Fibromyalgia, Bone fracture, Muscle sprain or strain, acute appendicitis, and others. With the increased prevalence of cancer cases, there is a greater need for cancer patients to be treated effectively in terms of pain management. Cancer pain management requires a multimodal approach that includes pharmaceutical medicines like opioids and adjuvant medications, as well as non-pharmacological techniques like radiation therapy and nerve blocks. The emphasis is on promoting patient comfort and minimizing the impact of pain on everyday activities. Innovative medicines and pharmaceuticals are being developed to address this crucial part of cancer care as awareness and research in cancer pain management continue to grow.

Chronic pain holds the highest market share and is the fastest-growing segment in the U.S. pain management drug market

By Pain Type, the United States Pain Management Therapeutics Market is subdivided into Chronic Pain and Acute Pain. The powerful medications are commonly prescribed for severe acute and chronic pain. With a substantial number of individuals suffering from persistent pain conditions, there is a pressing need for effective management options. The market offers a wide range of pharmaceutical treatments, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and antidepressants, tailored to address different types of chronic pain. Additionally, advancements in technology, such as neurostimulation and targeted therapies, are reshaping the landscape of chronic pain management, providing individuals with new hope for alleviating their pain and improving their quality of life.

Online pharmacy market boasts the highest market share and is the fastest-growing segment in the U.S. pain management drug industry

By Distribution Channel, the United States Pain Management Therapeutics Market is broken up into Hospital Pharmacies, Retail pharmacies, and Online Pharmacies. With the convenience and accessibility of online platforms, individuals are increasingly turning to online pharmacies to fulfill their medication needs. Online pharmacies provide a wide choice of pain management pharmaceuticals, allowing people to get pain relief treatments without having to go to a regular pharmacy. The rising popularity of online shopping, along with rising demand for pain management pharmaceuticals, has contributed to the spectacular rise of the online pharmacy business in the US pain management sector.

Key Players

Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson, and Baxter International Inc. are prominent players in the pain management industry, as highlighted in our analysis. This includes investing in technology innovation to develop advanced pain management solutions, forming partnerships to leverage complementary expertise, expanding their presence in different regions, and engaging in mergers and acquisitions to broaden their product portfolios and market reach.

Renub Research latest report “US Pain Management Therapeutics Industry, Forecast By Therapeutics (Pharmaceuticals, Devices), Devices (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pumps, Neurostimulation), Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-Migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis and Others), Pain Type (Chronic Pain, Acute Pain), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Companies (Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson and Baxter International Inc)” provides a detailed analysis of US Pain Management Therapeutics Industry.

Therapeutics – Market has been covered from 2 viewpoints:

1. Pharmaceuticals
2. Devices

Devices – Market has been covered from 4 viewpoints:

1. Electrical Stimulators
2. Radiofrequency Ablation
3. Analgesic Infusion Pumps
4. Neurostimulation

Drug Class – Market has been covered from 7 viewpoints:

1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2. Anesthetics
3. Anticonvulsants
4. Anti-Migraine Agents
5. Antidepressants
6. Opioids
7. Nonnarcotic Analgesics

Indication – Market has been covered from 11 viewpoints:

1. Arthritic Pai
2. Neuropathic Pain
3. Cancer Pain
4. Chronic Back Pain
5. Post-Operative Pain
6. Migraine
7. Fibromyalgia
8. Bone Fracture
9. Muscle Sprain/Strain
10. Acute Appendicitis
11. Others

Distribution Channel – Market has been covered from 3 viewpoints:

1. Hospital Pharmacies
2. Retail Pharmacies
3. Online Pharmacies

Pain Type – Market has been covered from 2 viewpoints:

1. Chronic Pain
2. Acute Pain

Company Insights:

• Overview
• Recent Development
• Financial Insight

Companies Covered:

1. Eli Lilly and Company
2. Pfizer Inc.
3. GlaxoSmithKline plc
4. Novartis International AG
5. Merck & Co., Inc.
6. Abbott Laboratories
7. Johnson & Johnson
8. Baxter International Inc.


1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Pain Management Therapeutics Market
6. Market Share – United States Pain Management Therapeutics Market
6.1 By Therapeutics
6.1.1 By Devices
6.2 By Drug Class
6.3 By Indication
6.4 By Pain Type
6.5 By Distribution Channel
7. Therapeutics – United States Pain Management Therapeutics Market
7.1 Pharmaceuticals
7.2 Devices
7.2.1 Electrical Stimulators
7.2.2 Radiofrequency Ablation
7.2.3 Analgesic Infusion Pumps
7.2.4 Neurostimulation
8. Drug Class – United States Pain Management Therapeutics Market
8.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8.2 Anesthetics
8.3 Anticonvulsants
8.4 Anti-Migraine Agents
8.5 Antidepressants
8.6 Opioids
8.7 Non-Narcotic Analgesics
9. Indication – United States Pain Management Therapeutics Market
9.1 Arthritic Pain
9.2 Neuropathic Pain
9.3 Cancer Pain
9.4 Chronic Back Pain
9.5 Post-Operative Pain
9.6 Migraine
9.7 Fibromyalgia
9.8 Bone Fracture
9.9 Muscle Sprain/Strain
9.10 Acute Appendicitis
9.11 Others
10. Pain Type – United States Pain Management Therapeutics Market
10.1 Chronic Pain
10.2 Acute Pain
11. Distribution Channel – United States Pain Management Therapeutics Market
11.1 Hospital Pharmacies
11.2 Retail Pharmacies
11.3 Online Pharmacies
12. Porter's Five Forces Analysis – United States Pain Management Therapeutics Market
12.1 Threat of New Entry
12.2 The Bargaining Power of Buyer
12.3 Threat of Substitution
12.4 The Bargaining Power of Supplier
12.5 Competitive Rivalry
13. SWOT Analysis – United States Pain Management Therapeutics Market
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat
14. Key Players Analysis
14.1 Eli Lilly and Company
14.1.1 Overview
14.1.2 Recent Development
14.1.3 SWOT Analysis
14.1.4 Financial Insight
14.2 Pfizer Inc.
14.2.1 Overview
14.2.2 Recent Development
14.2.3 SWOT Analysis
14.2.4 Financial Insight
14.3 GlaxoSmithKline plc
14.3.1 Overview
14.3.2 Recent Development
14.3.3 SWOT Analysis
14.3.4 Financial Insight
14.4 Novartis International AG
14.4.1 Overview
14.4.2 Recent Development
14.4.3 SWOT Analysis
14.4.4 Financial Insight
14.5 Merck & Co., Inc.
14.5.1 Overview
14.5.2 Recent Development
14.5.3 SWOT Analysis
14.5.4 Financial Insight
14.6 Abbott Laboratories
14.6.1 Overview
14.6.2 Recent Development
14.6.3 SWOT Analysis
14.6.4 Financial Insight
14.7 Johnson & Johnson
14.7.1 Overview
14.7.2 Recent Development
14.7.3 SWOT Analysis
14.7.4 Financial Insight
14.8 Baxter International Inc.
14.8.1 Overview
14.8.2 Recent Development
14.8.3 SWOT Analysis
14.8.4 Financial Insight
List of Figures:
Figure-01: United States – Pain Management Therapeutics Market (Billion US$), 2018 – 2022
Figure-02: United States – Forecast for Pain Management Therapeutics Market (Billion US$), 2023 – 2030
Figure-03: Therapeutics – Pharmaceuticals Market (Billion US$), 2018 – 2022
Figure-04: Therapeutics – Forecast for Pharmaceuticals Market (Billion US$), 2023 – 2030
Figure-05: Therapeutics – Devices Market (Billion US$), 2018 – 2022
Figure-06: Therapeutics – Forecast for Devices Market (Billion US$), 2023 – 2030
Figure-07: Devices – Electrical Stimulators Market (Million US$), 2018 – 2022
Figure-08: Devices – Forecast for Electrical Stimulators Market (Million US$), 2023 – 2030
Figure-09: Devices – Radiofrequency Ablation Market (Million US$), 2018 – 2022
Figure-10: Devices – Forecast for Radiofrequency Ablation Market (Million US$), 2023 – 2030
Figure-11: Devices – Analgesic Infusion Pumps Market (Million US$), 2018 – 2022
Figure-12: Devices – Forecast for Analgesic Infusion Pumps Market (Million US$), 2023 – 2030
Figure-13: Devices – Neurostimulation Market (Million US$), 2018 – 2022
Figure-14: Devices – Forecast for Neurostimulation Market (Million US$), 2023 – 2030
Figure-15: Drug Class – Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (Billion US$), 2018 – 2022
Figure-16: Drug Class – Forecast for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (Billion US$), 2023 – 2030
Figure-17: Drug Class – Anesthetics Market (Billion US$), 2018 – 2022
Figure-18: Drug Class – Forecast for Anesthetics Market (Billion US$), 2023 – 2030
Figure-19: Drug Class – Anticonvulsants Market (Billion US$), 2018 – 2022
Figure-20: Drug Class – Forecast for Anticonvulsants Market (Billion US$), 2023 – 2030
Figure-21: Drug Class – Anti-Migraine Agents Market (Billion US$), 2018 – 2022
Figure-22: Drug Class – Forecast for Anti-Migraine Agents Market (Billion US$), 2023 – 2030
Figure-23: Drug Class – Antidepressants Market (Billion US$), 2018 – 2022
Figure-24: Drug Class – Forecast for Antidepressants Market (Billion US$), 2023 – 2030
Figure-25: Drug Class – Opioids Market (Billion US$), 2018 – 2022
Figure-26: Drug Class – Forecast for Opioids Market (Billion US$), 2023 – 2030
Figure-27: Drug Class – Non-Narcotic Analgesics Market (Billion US$), 2018 – 2022
Figure-28: Drug Class – Forecast for Non-Narcotic Analgesics Market (Billion US$), 2023 – 2030
Figure-29: Indication – Arthritic Pain Market (Billion US$), 2018 – 2022
Figure-30: Indication – Forecast for Arthritic Pain Market (Billion US$), 2023 – 2030
Figure-31: Indication – Neuropathic Pain Market (Billion US$), 2018 – 2022
Figure-32: Indication – Forecast for Neuropathic Pain Market (Billion US$), 2023 – 2030
Figure-33: Indication – Cancer Pain Market (Billion US$), 2018 – 2022
Figure-34: Indication – Forecast for Cancer Pain Market (Billion US$), 2023 – 2030
Figure-35: Indication – Chronic Back Pain Market (Billion US$), 2018 – 2022
Figure-36: Indication – Forecast for Chronic Back Pain Market (Billion US$), 2023 – 2030
Figure-37: Indication – Post-Operative Pain Market (Billion US$), 2018 – 2022
Figure-38: Indication – Forecast for Post-Operative Pain Market (Billion US$), 2023 – 2030
Figure-39: Indication – Migraine Market (Billion US$), 2018 – 2022
Figure-40: Indication – Forecast for Migraine Market (Billion US$), 2023 – 2030
Figure-41: Indication – Fibromyalgia Market (Billion US$), 2018 – 2022
Figure-42: Indication – Forecast for Fibromyalgia Market (Billion US$), 2023 – 2030
Figure-43: Indication – Bone Fracture Market (Million US$), 2018 – 2022
Figure-44: Indication – Forecast for Bone Fracture Market (Million US$), 2023 – 2030
Figure-45: Indication – Muscle Sprain/Strain Market (Million US$), 2018 – 2022
Figure-46: Indication – Forecast for Muscle Sprain/Strain Market (Million US$), 2023 – 2030
Figure-47: Indication – Acute Appendicitis Market (Million US$), 2018 – 2022
Figure-48: Indication – Forecast for Acute Appendicitis Market (Million US$), 2023 – 2030
Figure-49: Indication – Others Market (Million US$), 2018 – 2022
Figure-50: Indication – Forecast for Others Market (Million US$), 2023 – 2030
Figure-51: Pain Type – Chronic Pain Market (Billion US$), 2018 – 2022
Figure-52: Pain Type – Forecast for Chronic Pain Market (Billion US$), 2023 – 2030
Figure-53: Pain Type – Acute Pain Market (Million US$), 2018 – 2022
Figure-54: Pain Type – Forecast for Acute Pain Market (Million US$), 2023 – 2030
Figure-55: Pain Type – Hospital Pharmacies Market (Billion US$), 2018 – 2022
Figure-56: Pain Type – Forecast for Hospital Pharmacies Market (Billion US$), 2023 – 2030
Figure-57: Pain Type – Retail Pharmacies Market (Billion US$), 2018 – 2022
Figure-58: Pain Type – Forecast for Retail Pharmacies Market (Billion US$), 2023 – 2030
Figure-59: Pain Type – Online Pharmacies Market (Billion US$), 2018 – 2022
Figure-60: Pain Type – Forecast for Online Pharmacies Market (Billion US$), 2023 – 2030
Figure-61: Eli Lilly and Company – Global Revenue (Billion US$), 2018 – 2022
Figure-62: Eli Lilly and Company – Forecast for Global Revenue (Billion US$), 2023 – 2030
Figure-63: Pfizer Inc. – Global Revenue (Billion US$), 2018 – 2022
Figure-64: Pfizer Inc. – Forecast for Global Revenue (Billion US$), 2023 – 2030
Figure-65: GlaxoSmithKline plc – Global Revenue (Billion US$), 2018 – 2022
Figure-66: GlaxoSmithKline plc – Forecast for Global Revenue (Billion US$), 2023 – 2030
Figure-67: Novartis International AG – Global Revenue (Billion US$), 2018 – 2022
Figure-68: Novartis International AG – Forecast for Global Revenue (Billion US$), 2023 – 2030
Figure-69: Merck & Co., Inc. – Global Revenue (Billion US$), 2018 – 2022
Figure-70: Merck & Co., Inc. – Forecast for Global Revenue (Billion US$), 2023 – 2030
Figure-71: Abbott Laboratories – Global Revenue (Billion US$), 2018 – 2022
Figure-72: Abbott Laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2030
Figure-73: Johnson & Johnson – Global Revenue (Billion US$), 2018 – 2022
Figure-74: Johnson & Johnson – Forecast for Global Revenue (Billion US$), 2023 – 2030
Figure-75: Boehringer Ingelheim – Global Revenue (Billion US$), 2018 – 2022
Figure-76: Boehringer Ingelheim – Forecast for Global Revenue (Billion US$), 2023 – 2030
List of Tables:
Table-01: United States – Pain Management Therapeutics Market Share by Therapeutics (Percent), 2018 – 2022
Table-02: United States – Forecast for Pain Management Therapeutics Market Share by Therapeutics (Percent), 2023 – 2030
Table-03: United States – Pain Management Therapeutics Market Share by Devices (Percent), 2018 – 2022
Table-04: United States – Forecast for Pain Management Therapeutics Market Share by Devices (Percent), 2023 – 2030
Table-05: United States – Pain Management Therapeutics Market Share by Drug Class (Percent), 2018 – 2022
Table-06: United States – Forecast for Pain Management Therapeutics Market Share by Drug Class (Percent), 2023 – 2030
Table-07: United States – Pain Management Therapeutics Market Share by Indication (Percent), 2018 – 2022
Table-08: United States – Forecast for Pain Management Therapeutics Market Share by Indication (Percent), 2023 – 2030
Table-09: United States – Pain Management Therapeutics Market Share by Pain Type (Percent), 2018 – 2022
Table-10: United States – Forecast for Pain Management Therapeutics Market Share by Pain Type (Percent), 2023 – 2030
Table-11: United States – Pain Management Therapeutics Market Share by Distribution Channel (Percent), 2018 – 2022
Table-12: United States – Forecast for Pain Management Therapeutics Market Share by Distribution Channel (Percent), 2023 – 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings